Amgen Inc. · NASDAQ:AMGN
Amgen — Investor Presentation (December 2023)
13 slides from Amgen's investor presentation, Dec 7, 2023
Slide 1: Investor Presentation
Investor Presentation December 2023 Justin Claeys, Vice President Investor Relations Ann Hyllengren, Senior Director Investor Relations Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outco
Slide 3: Amgen at a glance
FOUNDED GLOBAL HQ EMPLOYEES 1980 Thousand Oaks, California, USA 25,000+ # OF PATIENTS REACHED R&D INVESTMENT DONATIONS ~10 million $4.4 billion $2.2 billion* ANNUALLY IN 2022 Through AMGEN SAFETY NET FOUNDATION IN 2022 MARKETS TOTAL REVENUE ~100 $26.3 billion IN 2022 Provided December 7, 2023, as pa
Slide 4: Our Products Reflect Our Commitment To Serving Patients Living With Serious Illness
Our Products Reflect Our Commitment To Serving Patients Living With Serious Illness Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update
Slide 5: Therapeutic areas and indications served
Acute Lymphoblastic Rheumatoid Leukemia Arthritis Melanoma Cancer Severe Non-small Cell Asthma Multiple Lung Cancer Plaque Crohn’s Myeloma Psoriasis Disease Colorectal ANCA-associated Non-Hodgkin’s Cancer vasculitis Lymphoma Thyroid Eye Disease Adjuvant Uncontrolled Gout Breast Cancer Heart Attack O
Slide 6: Portfolio Of Leading Products With Significant Growth Potential
Portfolio Of Leading Products With Significant Growth Potential Inflammation Oncology General Medicine Only oral systemic 44% volume therapy for psoriasis growth* with a broad indication 7% volume growth* Launch off to strong start 48% volume growth* 15% total volume growth* *Growth rates represent
Slide 7: Advancing Pipeline Of Potentially First-in-class Molecules Targeting Serious Diseases
Advancing Pipeline Of Potentially First-in-class Molecules Targeting Serious Diseases INFLAMMATION ONCOLOGY GENERAL MEDICINE TEZSPIRE® approved in severe asthma BLINCYTO® approved in B-ALL, moving Repatha approved in hyperlipidemia and and being studied for new indications into earlier lines of trea
Slide 8: A Few Comments From Our Q3 '23 Earnings
A Few Comments From Our Q3 ’23 Earnings • Drove volume growth with our innovative brands and raised 2023 FY Guidance ◦ 11% volume growth achieved in Q3’23 • Closed the Horizon Therapeutics transaction (Oct 6, 2023) ◦ Added Horizon’s rare disease medicines to our broad innovative portfolio • Expanded
Slide 9: Industry-Leading Biosimilars Business Accretive To Long-term Growth
Industry- Leading Biosimilars Business Accretive To Long-term Growth Future Launches & Pipeline* Currently Commercialized BEKEMV, biosimilar to SOLIRIS® WEZLANA, biosimilar to STELARA® ABP 938, investigational biosimilar to EYLEA® ABP 206, investigational biosimilar to OPDIVO® + 2 other molecules AT
Slide 10: We Are Investing in Our Research Capabilities
We Are Investing in Our Research Capabilities Investing for over a decade to prepare for the convergence of science and technology • Leveraging human data • Pursuing multispecifics to drug the “undruggable” • Building leadership in generative biology - Biologics NExT Provided December 7, 2023, as pa
Slide 11: We Are Advancing Our ESG Agenda
We Are Advancing Our ESG Agenda We are on track to We are focused on We are serving patients in the achieve our 2027 Diversity, Inclusion, and low- and middle- income ambition Belonging countries (LMICs) ✓ Signed multiple partnership agreements for Health system strengthening and improving access fo
Slide 12: We Continue Returning Capital to Our Shareholders
We Continue Returning Capital to Our Shareholders Amgen Dividend: 2011 – 2022 We increased our dividends for the first nine months of 2023 by an additional 10% $7.76 $7.04 $6.40 $5.80 $5.28 $4.60 $4.00 $3.16 $2.44 $1.88 $1.44 $1.12 2011* 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Provide
Slide 13: We Are Focused On Executing Against Our Long-Term Objectives
We Are Focused On Executing Against Our Long-Term Objectives • Integrate and grow our new rare disease business • Advance our first-in-class, best-in-class innovative pipeline • Deliver strong financial performance; focused on volume growth • Expand international footprint • Continue industry leader